Tegretol CR 200mg is a prescription medicine from Novartis containing carbamazepine, an antiepileptic ingredient used in selected neurological conditions. Each controlled-release tablet contains 200mg of carbamazepine. The formulation is designed to release the active ingredient gradually, supporting a prescribed dosing schedule. This presentation contains 50 film-coated tablets in blister packaging.
Tegretol CR 200mg must be taken according to the prescribing physician's instructions. The appropriate dose and frequency depend on the condition, age, response and other medicines being used. Tablets are generally taken with or after food and swallowed with water. The scored controlled-release tablets may be divided when the approved leaflet and prescribed dose allow, but should not be chewed or crushed. Do not stop the medicine suddenly without medical supervision, particularly when prescribed for epilepsy. Regular monitoring may include blood counts, liver function and sodium levels. Seek urgent medical advice if a significant rash, blistering, unusual bruising, fever or severe dizziness develops. Pregnancy planning and potential medicine interactions require specialist discussion.
Carbamazepine acts on voltage-gated sodium channels in nerve cells, helping stabilise electrical activity and reduce repetitive nerve signalling. This mechanism supports management of certain seizure disorders and selected neuropathic pain conditions. The controlled-release design distributes the release of carbamazepine over an extended period rather than delivering the entire amount immediately. Tegretol CR 200mg is intended for regular, supervised use within an individual medical care plan.
The active ingredient is carbamazepine 200mg. The controlled-release formulation includes colloidal silicon dioxide, ethylcellulose dispersion, microcrystalline cellulose, an ethyl acrylate and methyl methacrylate copolymer, magnesium stearate, croscarmellose sodium and talc. Coating ingredients include hypromellose, macrogolglycerol hydroxystearate, iron oxides and titanium dioxide. The supplied leaflet provides complete formulation details.
Tegretol CR 200mg provides a defined carbamazepine strength in a controlled-release tablet suitable for physician-directed neurological care. Its formulation is designed to support consistent medicine administration according to the prescribed regimen.
The registered 50-tablet Tegretol CR 200mg presentation is manufactured by Novartis Farma S.p.A. in Italy. Each pack contains 50 controlled-release tablets. Store below 30°C in the original packaging to protect from moisture, and keep out of children's reach. It is available at Pharmacy Plus Kuwait.